Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Loading...
We’re glad to see you’re enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.